Vinva Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vinva Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	30,687 +21,156	+222%	+$9.38M	0.1%	179
2026 Q1	$4.22M	Sell	9,531 -1,407	-13%	-$656K	0.05%	228
2025 Q4	$4.96M	Buy	10,938 +2,303	+27%	+$993K	0.06%	208
2025 Q3	$3.41M	Sell	8,635 -1,710	-17%	-$715K	0.07%	219
2025 Q2	$4.57M	Sell	10,345 -2,792	-21%	-$1.29M	0.12%	173
2025 Q1	$6.47M	Buy	13,137 +9,625	+274%	+$4.49M	0.26%	101
2024 Q4	$1.4M	Buy	3,512 +1,069	+44%	+$496K	0.05%	260
2024 Q3	$1.13M	Sell	2,443 -6,784	-74%	-$3.26M	0.05%	280
2024 Q2	$4.36M	Sell	9,227 -479	-5%	-$208K	0.22%	113
2024 Q1	$4.06M	Buy	9,706 +703	+8%	+$297K	0.23%	113
2023 Q4	$3.68M	Buy	9,003 +1,006	+13%	+$372K	0.25%	101
2023 Q3	$2.82M	Buy	7,997 +121	+2%	+$42.3K	0.26%	89
2023 Q2	$2.74M	Sell	7,876 -881	-10%	-$297K	0.24%	106
2023 Q1	$2.73M	Buy	+8,757	New	+$2.63M	0.23%	116

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vinva Investment Management's VRTX Position: Q2 2026 in Review

Vinva Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 222% in Q2 2026, buying an estimated $9.38M and bringing the position to 30,687 shares worth $15.3M. The position accounts for 0.1% of the portfolio, ranked #179.

Vinva Investment Management first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Vinva Investment Management held 30,687 shares of Vertex Pharmaceuticals worth $15.3M as of Q2 2026.
Vinva Investment Management bought 21,156 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.38M.
Vertex Pharmaceuticals made up 0.1% of Vinva Investment Management's portfolio in Q2 2026, its #179 holding.
Vinva Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.